NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab

被引：1

作者：

Signoriello, Elisabetta ^{[1
]}

Signori, Alessio ^{[2
]}

Lus, Giacomo ^{[1
]}

Romano, Giuseppe ^{[1
]}

Marfia, Girolama Alessandra ^{[3
]}

Landi, Doriana ^{[3
]}

Napoli, Francesca ^{[3
]}

D'Amico, Emanuele ^{[4
]}

Zanghi, Aurora ^{[4
]}

Di Filippo, Paola Sofia ^{[4
]}

Caliendo, Daniele ^{[5
]}

Carotenuto, Antonio ^{[5
]}

Spiezia, Antonio Luca ^{[5
]}

Fantozzi, Roberta ^{[6
]}

Centonze, Diego ^{[6
,7
]}

Lucchini, Matteo ^{[8
,9
]}

Mirabella, Massimiliano ^{[8
,9
]}

Cocco, Eleonora ^{[10
,11
]}

Frau, Jessica ^{[10
]}

Mniscalco, Giorgia Teresa ^{[12
]}

Di Battista, Maria Elena ^{[12
]}

Foschi, Metteo ^{[13
,14
]}

Surcinelli, Andrea ^{[13
]}

Bonavita, Simona ^{[15
]}

Abbadessa, Gianmarco ^{[15
]}

Pasquali, Livia ^{[16
]}

Di Gregorio, Maria ^{[17
]}

Ferro, Maria Teresa ^{[18
]}

Sormani, Maria Pia ^{[2
,19
]}

Schiavetti, Irene ^{[2
]}

机构：

[1] Univ Campania Luigi Vanvitelli, Div Neurol 2, Naples, Italy

[2] Univ Genoa, Dept Hlth Sci, Sect Biostat, Genoa, Italy

[3] Tor Vergata Univ, Dept Syst Med, Multiple Sclerosis Clin & Res Unit, Rome, Italy

[4] Univ Foggia, Dept Med & Surg Sci, Foggia, Italy

[5] Federico II Univ Naples, Dept Neurosci Reprod Sci & Odontostomatol, Naples, Italy

[6] IRCCS Neuromed, I-86077 Pozzilli, Italy

[7] Tor Vergata Univ, Dept Syst Med, I-00133 Rome, Italy

[8] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy

[9] Univ Cattolica Sacro Cuore, CERSM, Rome, Italy

[10] ASL Cagliari, Multiple Sclerosis Ctr, Cagliari, Italy

[11] Univ Cagliari, Dpt Med Sci & Publ Hlth, Cagliari, Italy

[12] A Cardarelli Hosp, MS & Neuroimmunol Ctr, Naples, Italy

[13] AUSL Romagna, Multiple Sclerosis Ctr, Dept Neurosci, Neurol Unit,S Mariadelle Croci Hosp, Ravenna, Italy

[14] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy

[15] Univ Campania Luigi Vanvitelli, Dept Med Surg Neurol Metab & Aging Sci, Clin Neurol 1, Naples, Italy

[16] Univ Pisa, Dept Clin & Expt Med, Neurol Unit, Pisa, Italy

[17] Univ Hosp San Giovanni Dio & Ruggi Aragona, Neurol Unit, I-84100 Salerno, Italy

[18] ASST Crema, Neuroimmunol & Multiple Sclerosis Ctr, Crema, Italy

[19] IRCCS Osped Policlin San Martino, Genoa, Italy

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2024年 / 87卷

关键词：

Multiple sclerosis; NEDA-3; Ocrelizumab; Natalizumab; Highly active MS patients (HAMS); High-efficacy disease-modifying therapy (HE; DMTs); INTERFERON BETA-1A;

D O I：

10.1016/j.msard.2024.105594

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background: in the early stages of Multiple Sclerosis (MS), initiating high-efficacy disease-modifying therapy (HE DMTs) may represent an optimal strategy for delaying neurological damage and long-term disease progression, especially in highly active MS patients (HAMS). Natalizumab (NAT) and Ocrelizumab (OCR) are recognized as HE DMTs with significant anti-inflammatory effects. This study investigates NEDA-3 achievement in treatmentna & iuml;ve HAMS patients receiving NAT or OCR over three years. Methods: we retrospectively enrolled treatment-na & iuml;ve HAMS patients undergoing NAT or OCR, collecting demographic, clinical, and instrumental data before and after treatment initiation to compare with propensity score analysis disease activity, time to disability worsening, and NEDA-3 achievement.

引用

页数：7

共 50 条

[1] Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis
Cobo-Calvo, Alvaro
Bau, Laura
Matas, Elisabet
Romero-Pinel, Lucia
Mane Martinez, M. Alba
Majos, Carles
Martinez Yelamos, Sergio
EUROPEAN NEUROLOGY, 2015, 73 (3-4) : 220 - 229
[2] Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
Diem, Lara
Nedeltchev, Krassen
Kahles, Timo
Achtnichts, Lutz
Findling, Oliver
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
[3] Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
van Lierop, Z. Y. G. J.
Toorop, A. A.
Coerver, E. M. E.
Willemse, E. A. J.
Strijbis, E. M. M.
Kalkers, N. F.
Moraal, B.
Barkhof, F.
Teunissen, C. E.
Killestein, J.
van Kempen, Z. L. E.
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2021, 7 (02)
[4] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
Cavit Boz
Serkan Ozakbas
Murat Terzi
Rana Karabudak
Serhan Sevim
Recai Turkoglu
Aysun Soysal
Belgin Petek Balcı
Hüsnü Efendi
Ömer Faruk Turan
Nur Yüceyar
Mehmet Fatih Yetkin
Serap Zengin Karahan
Meltem Demirkıran
Sibel Guler
Kadriye Agan
Nefati Kıylıoğlu
Cavid Baba
Asli Tuncer
Mesrure Köseoğlu
Neurological Sciences, 2023, 44 : 2121 - 2129
[5] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
Boz, Cavit
Ozakbas, Serkan
Terzi, Murat
Karabudak, Rana
Sevim, Serhan
Turkoglu, Recai
Soysal, Aysun
Balci, Belgin Petek
Efendi, Husnu
Turan, Omer Faruk
Yuceyar, Nur
Yetkin, Mehmet Fatih
Karahan, Serap Zengin
Demirkiran, Meltem
Guler, Sibel
Agan, Kadriye
Kiylioglu, Nefati
Baba, Cavid
Tuncer, Asli
Koseoglu, Mesrure
NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
[6] Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study
D'Amico, Emanuele
Zanghi, Aurora
Calogero, Aldo Eugenio
Patti, Francesco
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (14) : 2284 - 2287
[7] Subcutaneously delivered natalizumab for the treatment of highly active relapsing-remitting multiple sclerosis
Haluskova, S.
Valis, M.
CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2022, 85 (03) : 206 - 212
[8] Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
Alroughani, R.
Al Hashel, J.
Thussu, A.
Ahmed, S. F.
MEDICAL PRINCIPLES AND PRACTICE, 2013, 22 (05) : 495 - 499
[9] No evidence of disease activity including cognition (NEDA-3 plus) in naive pediatric multiple sclerosis patients treated with natalizumab
Margoni, Monica
Rinaldi, Francesca
Riccardi, Alice
Franciotta, Silvia
Perini, Paola
Gallo, Paolo
JOURNAL OF NEUROLOGY, 2020, 267 (01) : 100 - 105
[10] Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
Mansour A. Alharbi
Fahad Aldosari
Ahmed Hasan Althobaiti
Faris M. Abdullah
Salman Aljarallah
Nuha M. Alkhawajah
Miteb Alanazi
Yazed AlRuthia
BMC Health Services Research, 23

← 1 2 3 4 5 →